PTC Therapeutics (PTCT) PT Raised to $90 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Price: $62.72 +0.16%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Join SI Premium – FREE
UBS analyst Joon Lee raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $90.00 (from $80.00) while maintaining a Buy rating.
You May Also Be Interested In
- Crown Castle (CCI) PT Lowered to $91 at BMO Capital Following Mixed Results
- Lam Research (LRCX) PT Lowered to $350 at Bernstein SocGen Group
- Meta Platforms Inc. (META) PT Raised to $950 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
